N-(2-(4-(2-(1H-indol-2-yl)ethyl)piperazin-1-yl)-5-bromophenyl)-2-(phenylimino)-2H-chromene-3-carboxamide | 1429200-29-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-(4-(2-(1H-indol-2-yl)ethyl)piperazin-1-yl)-5-bromophenyl)-2-(phenylimino)-2H-chromene-3-carboxamide
• 英文别名: N-[5-bromo-2-[4-[2-(1H-indol-2-yl)ethyl]piperazin-1-yl]phenyl]-2-phenyliminochromene-3-carboxamide
• CAS: 1429200-29-2
• 化学式: C₃₆H₃₂BrN₅O₂
• 分子量: 646.586
• InChiKey: YTIUQAJUUIPSNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  44
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  73
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,5-二溴硝基苯 在 哌啶 、 sodium dithionate 、 sodium carbonate 、 potassium carbonate 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 水 、 异丙醇 、 甲苯 为溶剂， 反应 39.0h， 生成 N-(2-(4-(2-(1H-indol-2-yl)ethyl)piperazin-1-yl)-5-bromophenyl)-2-(phenylimino)-2H-chromene-3-carboxamide
  参考文献：
  名称：

  Phenylimino-2 H -chromen-3-carboxamide derivatives as novel small molecule inhibitors of β-secretase (BACE1)

  摘要：

  The inhibition of beta secretase (BACE1) is potentially important approach to treatment of Alzheimer disease (AD). A novel series of 4-bromophenyl piperazine derivatives coupled to the phenylimino-2H-chromen-3-carboxamide scaffold were investigated as BACE1 inhibitors in this study. Docking study suggested that the phenyl-imino group of the scaffold establishes favorable p-p stacking interaction with side chain of Phe108 of flap pocket. Some of the docking proposed derivatives were synthesized and evaluated for BACE1 inhibitory activity using a FRET-based assay. High BACE1 inhibitory activities were observed from derivatives containing fused heteroaromtic groups attached through the aliphatic linkage to the N4-piperazine moiety, which may be attributed to the engagement of effective interactions with S1-S'1 sub-pocket residues. Of the most potent compounds, 9e displayed an IC50 value for BACE1 of 98 nM. Some of these derivatives demonstrated good inhibitory activity on A beta production in N2a-APPswe cells at 5 and 10 mu M. These compounds might be considered as promising BACE1 inhibitory agents that could lower A beta production in AD. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.01.064

文献信息

• Phenylimino-2 H -chromen-3-carboxamide derivatives as novel small molecule inhibitors of β-secretase (BACE1)
  作者：Najmeh Edraki、Omidreza Firuzi、Alireza Foroumadi、Ramin Miri、Armin Madadkar-Sobhani、Mehdi Khoshneviszadeh、Abbas Shafiee

  DOI：10.1016/j.bmc.2013.01.064

  日期：2013.4

  The inhibition of beta secretase (BACE1) is potentially important approach to treatment of Alzheimer disease (AD). A novel series of 4-bromophenyl piperazine derivatives coupled to the phenylimino-2H-chromen-3-carboxamide scaffold were investigated as BACE1 inhibitors in this study. Docking study suggested that the phenyl-imino group of the scaffold establishes favorable p-p stacking interaction with side chain of Phe108 of flap pocket. Some of the docking proposed derivatives were synthesized and evaluated for BACE1 inhibitory activity using a FRET-based assay. High BACE1 inhibitory activities were observed from derivatives containing fused heteroaromtic groups attached through the aliphatic linkage to the N4-piperazine moiety, which may be attributed to the engagement of effective interactions with S1-S'1 sub-pocket residues. Of the most potent compounds, 9e displayed an IC50 value for BACE1 of 98 nM. Some of these derivatives demonstrated good inhibitory activity on A beta production in N2a-APPswe cells at 5 and 10 mu M. These compounds might be considered as promising BACE1 inhibitory agents that could lower A beta production in AD. (C) 2013 Elsevier Ltd. All rights reserved.